Loading clinical trials...
Loading clinical trials...
Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.
Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease expression and course is unknown. This study will evaluate the relationship between obesity, obesity-derived inflammatory mediators, and imaging metrics of MS severity in children. Understanding how childhood obesity contributes to MS severity/progression may yield fundamental insights into disease pathobiology - which may thereby lead to effective strategies for halting its progression in its earliest stages.
Age
10 - 20 years
Sex
ALL
Healthy Volunteers
Yes
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Virginia
Charlottesville, Virginia, United States
Start Date
June 3, 2021
Primary Completion Date
June 1, 2025
Completion Date
June 1, 2025
Last Updated
December 9, 2024
116
ESTIMATED participants
Lead Sponsor
University of Virginia
Collaborators
NCT07225504
NCT06276634
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809192